NICOLS JOHN J
Known title: President and CEOCIK: 0001238884
Associated companies
Transaction History
| CDXS | ▲ Buy | Option Exercise | 35,714 | $70K | 4/18/2023 | View on chart |
| CDXS | ▼ Sell | Open Market | 35,714 | $148K | 4/18/2023 | View on chart |
| CDXS | ▲ Buy | Option Exercise | 35,714 | $70K | 4/17/2023 | View on chart |
| CDXS | ▼ Sell | Open Market | 35,714 | $151K | 4/17/2023 | View on chart |
| CDXS | ▲ Buy | Option Exercise | 35,714 | $70K | 3/16/2023 | View on chart |
| CDXS | ▼ Sell | Open Market | 35,714 | $147K | 3/16/2023 | View on chart |
| CDXS | ▲ Buy | Option Exercise | 35,714 | $70K | 3/15/2023 | View on chart |
| CDXS | ▼ Sell | Open Market | 35,714 | $146K | 3/15/2023 | View on chart |
| CDXS | ▲ Buy | Option Exercise | 35,714 | $70K | 2/24/2023 | View on chart |
| CDXS | ▼ Sell | Open Market | 35,714 | $173K | 2/24/2023 | View on chart |
| CDXS | ▼ Sell | Open Market | 39,785 | $213K | 2/23/2023 | View on chart |
| CDXS | ▲ Buy | Option Exercise | 35,714 | $70K | 1/24/2023 | View on chart |
| CDXS | ▼ Sell | Open Market | 35,714 | $229K | 1/24/2023 | View on chart |
| CDXS | ▼ Sell | Open Market | 39,785 | $262K | 1/23/2023 | View on chart |
| CDXS | ▲ Buy | Option Exercise | 35,714 | $70K | 12/12/2022 | View on chart |
| CDXS | ▼ Sell | Open Market | 35,714 | $203K | 12/12/2022 | View on chart |
| CDXS | ▼ Sell | Open Market | 39,785 | $225K | 12/9/2022 | View on chart |
| CDXS | ▲ Buy | Option Exercise | 35,714 | $70K | 11/16/2022 | View on chart |
| CDXS | ▼ Sell | Open Market | 35,714 | $227K | 11/16/2022 | View on chart |
| CDXS | ▼ Sell | Open Market | 39,786 | $270K | 11/15/2022 | View on chart |
| CDXS | ▲ Buy | Option Exercise | 35,716 | $70K | 10/28/2022 | View on chart |
| CDXS | ▼ Sell | Open Market | 35,716 | $198K | 10/28/2022 | View on chart |
| CDXS | ▼ Sell | Open Market | 39,786 | $226K | 10/27/2022 | View on chart |
| CDXS | ▲ Buy | Option Exercise | 35,716 | $70K | 10/6/2022 | View on chart |
| CDXS | ▼ Sell | Open Market | 35,716 | $214K | 10/6/2022 | View on chart |
| CDXS | ▼ Sell | Open Market | 39,787 | $240K | 10/5/2022 | View on chart |
| CDXS | ▲ Buy | Option Exercise | 39,000 | $90K | 8/15/2022 | View on chart |
| CDXS | ▼ Sell | Open Market | 39,000 | $343K | 8/15/2022 | View on chart |
| CDXS | ▲ Buy | Option Exercise | 38,500 | $89K | 8/12/2022 | View on chart |
| CDXS | ▼ Sell | Open Market | 38,500 | $332K | 8/12/2022 | View on chart |
| CDXS | ▲ Buy | Option Exercise | 38,500 | $89K | 5/12/2022 | View on chart |
| CDXS | ▼ Sell | Open Market | 16,409 | $174K | 5/12/2022 | View on chart |
| CDXS | ▼ Sell | Open Market | 22,091 | $223K | 5/12/2022 | View on chart |
| CDXS | ▲ Buy | Option Exercise | 38,500 | $89K | 5/11/2022 | View on chart |
| CDXS | ▼ Sell | Open Market | 38,500 | $397K | 5/11/2022 | View on chart |
| CDXS | ▲ Buy | Option Exercise | 38,500 | $89K | 3/10/2022 | View on chart |
| CDXS | ▼ Sell | Open Market | 38,500 | $729K | 3/10/2022 | View on chart |
| CDXS | ▲ Buy | Option Exercise | 38,500 | $89K | 3/9/2022 | View on chart |
| CDXS | ▼ Sell | Open Market | 38,500 | $743K | 3/9/2022 | View on chart |
| CDXS | ▲ Buy | Option Exercise | 38,500 | $89K | 11/11/2021 | View on chart |
| CDXS | ▼ Sell | Open Market | 27,173 | $1.0M | 11/11/2021 | View on chart |
| CDXS | ▼ Sell | Open Market | 11,327 | $443K | 11/11/2021 | View on chart |
| CDXS | ▼ Sell | Open Market | 14,071 | $561K | 11/10/2021 | View on chart |
| CDXS | ▲ Buy | Option Exercise | 35,000 | $121K | 11/10/2021 | View on chart |
| CDXS | ▼ Sell | Open Market | 19,454 | $792K | 11/10/2021 | View on chart |
| CDXS | ▼ Sell | Open Market | 1,475 | $58K | 11/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Codexis Signs siRNA Manufacturing Deal
Codexis has entered an agreement with an unnamed siRNA drug innovator to use its ECO Synthesis platform for stereo-defined fragment synthesis. This partnership highlights the company's manufacturing capabilities in a growing therapeutic area. The stock is currently trading near its 52-week low, with recent price action showing rejection at support levels.
Codexis Signs siRNA Manufacturing Deal. Codexis has entered an agreement with an unnamed siRNA drug innovator to use its ECO Synthesis platform for stereo-defined fragment synthesis. This partnership highlights the company's manufacturing capabilities in a growing therapeutic area. The stock is currently trading near its 52-week low, with recent price action showing rejection at support levels.